Oncimmune Holdings PLC
LSE:ONC
Oncimmune Holdings PLC
LSE:ONC
Price:
22.648 GBX
-1.53%
Market Closed
Updated:
May 7, 2024
Section:
Relative Value
The Relative Value of one
ONC
stock under the Base Case scenario is
24.976
GBX.
Compared to the current market price of 22.648 GBX,
Oncimmune Holdings PLC
is
Undervalued by 9%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ONC
Relative Value
Base Case
24.976
GBX
Undervaluation 9%
Valuation Multiples
Multiples Across Competitors
ONC Competitors Multiples
Oncimmune Holdings PLC Competitors
Oncimmune Holdings PLC Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| UK |
|
Oncimmune Holdings PLC
LSE:ONC
|
16.8m GBP | 14.6 | 4.1 | -6.3 | -4.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
286.9B USD | 5.3 | 59.5 | 13 | 19.8 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
162.1B USD | 5.5 | 43.1 | 18.3 | 30.1 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
105.9B USD | 8.1 | 27.4 | 22.2 | 24.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
105.9B USD | 10.7 | 29.2 | 23.2 | 24.3 | |
| AU |
|
CSL Ltd
ASX:CSL
|
135.1B AUD | 6.3 | 36.2 | 21.9 | 27.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.9B USD | 3 | 169.3 | 6.8 | 8.9 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
46B USD | 8.9 | -7.7 | -8.3 | -7.4 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.6B USD | 3.3 | 27.1 | 14 | 17.5 | |
| KR |
|
Celltrion Inc
KRX:068270
|
40.3T KRW | 18.5 | 75.2 | 46 | 63.3 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
